Please assess the completion status of the following clinical trial:

Trial Title: A Study of Baricitinib (LY3009104) in Participants With Moderate-to-Severe Atopic Dermatitis

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE2
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Have moderate-to-severe Atopic Dermatitis (AD), as determined by all of the following:~  1. EASI of 12 or more~ 2. Greater than or equal to 10% of body surface area involvement~ 3. Diagnosed with AD at least 2 years prior~* Have a history of inadequate clinical response to other eczema treatments~Exclusion Criteria:~* Females who are pregnant or nursing~* Participants who do not agree to use adequate contraception~* Are currently experiencing or have a history of:~  * Skin conditions such as psoriasis or lupus erythematosus~ * Skin disease that requires frequent hospitalizations or intravenous treatment~ * Compromised immunity~* Serious illness that could interfere with study participation, or a clinically important deviation in physical examination, vital sign measurements, electrocardiograms, or abnormalities on laboratory tests~* Currently experiencing or have a history of:~  * Active or latent Tuberculosis or specific immunity disorders and infections~ * Malignancy or lymphoproliferative diseases in the last 5 years (or cervical, basal or squamous skin cancer re-occurrence in the last 3 years)~ * Human Immunodeficiency Virus (HIV)~ * Hepatitis B, Hepatitis C, or chronic liver disease~* Have received certain types of vaccinations

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Baricitinib (Type: EXPERIMENTAL): Administered once daily in multiple oral dose cohorts for 16 weeks~(Triamcinolone 0.1% topical also permitted)
- Placebo (Type: PLACEBO_COMPARATOR): Administered orally once daily, for 16 weeks~(Triamcinolone 0.1% topical also permitted)

Based on this trial design, predict the completion outcome and termination type (if applicable).